Charles River Laboratories International
CRL · NYSEServices-Commercial Physical & Biological Research · Fiscal year ends Dec 27
Charles River Laboratories International reported revenue of $4B in the fiscal year ended Dec 2025, down 0.9% from the year before. Operating income was $25M, an operating margin of 0.6%, and net income was −$144M. Operating cash flow of $738M less capital expenditure of $219M left free cash flow of $518M. Net debt was $1.9B.
Last 5 fiscal years
Revenue and net income
Income statement
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | $3.5B | $4B | $4.1B | $4B | $4B |
| Selling, general & admin | $620M | $665M | $748M | $751M | $743M |
| Operating income | $590M | $651M | $617M | $227M | $25M |
| Interest expense | $74M | $59M | $137M | $126M | $107M |
| Pre-tax income | $481M | $623M | $581M | $93M | −$100M |
| Income tax | $82M | $130M | $101M | $68M | $43M |
| Net income | $391M | $486M | $475M | $22M | −$144M |
| Diluted EPS | 7.60 | 9.48 | 9.22 | 0.20 | −2.91 |
| Diluted shares | 51M | 51M | 51M | 52M | 50M |
Balance sheet
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Cash & equivalents | $241M | $234M | $277M | $195M | $214M |
| Receivables | $643M | $752M | $780M | $721M | $709M |
| Inventory | $199M | $256M | $380M | $279M | $299M |
| Current assets | $1.3B | $1.4B | $1.6B | $1.4B | $1.4B |
| Net PP&E | $1.3B | $1.5B | $1.6B | $1.6B | $1.7B |
| Goodwill | $2.7B | $2.8B | $3.1B | $2.8B | $2.8B |
| Total assets | $7B | $7.6B | $8.2B | $7.5B | $7.1B |
| Payables | $198M | $206M | $169M | $140M | $149M |
| Deferred revenue | $220M | $264M | $242M | $248M | $210M |
| Current liabilities | $1B | $1.1B | $1.1B | $994M | $1.1B |
| Short-term debt | $101,000 | $1M | $3M | $155,000 | $166,000 |
| Long-term debt | $2.7B | $2.7B | $2.6B | $2.2B | $2.1B |
| Total liabilities | $4.4B | $4.6B | $4.5B | $4B | $3.9B |
| Shareholders' equity | $2.5B | $3B | $3.6B | $3.5B | $3.2B |
| Backlog (remaining obligations) | $716M | $1.2B | $986M | $789M | $667M |
Cash flow
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating cash flow | $761M | $620M | $684M | $735M | $738M |
| Capital expenditure | $229M | $325M | $319M | $233M | $219M |
| Free cash flow | $532M | $295M | $365M | $502M | $518M |
| Depreciation & amortisation | $266M | $304M | $314M | $362M | $403M |
| Stock-based compensation | $71M | $74M | $72M | $70M | $71M |
| Acquisitions | $1.3B | $283M | $195M | $5M | $0 |
| Share buybacks | $41M | $39M | $24M | $119M | $361M |
Key ratios
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue growth (YoY) | – | 12.3% | 3.9% | −1.9% | −0.9% |
| Operating income growth (YoY) | – | 10.4% | −5.2% | −63.2% | −88.9% |
| EPS growth (YoY) | – | 24.7% | −2.7% | −97.8% | −1555.0% |
| Operating margin | 16.7% | 16.4% | 14.9% | 5.6% | 0.6% |
| Net margin | 11.0% | 12.2% | 11.5% | 0.5% | −3.6% |
| Return on equityBlank when equity is negative | 15.4% | 16.3% | 13.2% | 0.6% | −4.6% |
| ROCEEBIT ÷ (assets − current liabilities) | 9.8% | 10.0% | 8.6% | 3.5% | 0.4% |
| Free cash flow margin | 15.0% | 7.4% | 8.8% | 12.4% | 12.9% |
| Cash conversion (CFO ÷ net income) | 1.95x | 1.27x | 1.44x | 33.1x | −5.11x |
| Receivable days | 66 | 69 | 69 | 65 | 64 |
| Interest cover | 7.98x | 11.0x | 4.52x | 1.80x | 0.24x |
| Debt ÷ equity | 1.05x | 0.91x | 0.74x | 0.65x | 0.68x |
| Net debtDebt − cash & equivalents; excludes investments; negative = net cash | $2.4B | $2.5B | $2.4B | $2B | $1.9B |
| Current ratio | 1.23x | 1.32x | 1.52x | 1.41x | 1.29x |
Recent filings
More in Services-Commercial Physical & Biological Research
Standardised figures from the company's XBRL filings with the SEC (10-K, 10-Q). Line items follow US GAAP tags, so a company's own statement layout may differ and some lines show “–” where the company does not report that item. Ratios are calculated from these figures. For education only; not investment advice or a recommendation.